Adebrelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Resectable NSCLC
Clinical trial NCT07567326 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07567326
- Sponsor
- Peking University Cancer Hospital & Institute
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-07-01
- Primary completion
- 2028-12-01
- Enrollment
- 78
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.